Granisetron 1 Mg/Ml (1 Ml) Fresenius, Granisetron 1 Mg/Ml (3 Ml) Fresenius 1 ml, 3 ml Concentrate for solution for injection/infusion.
PDF Leaflet Revision Date: 29 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and post-operative.
Dosage (summary)
Adults: 1-3 mg IV/IM prior to chemotherapy; max 9 mg/24h.
Onset of Action / Duration
Onset: 30 secs, Duration: up to 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Preferable to avoid during pregnancy; breastfeeding not advisable.
Key Drug Interactions
- QT prolonging agents
- Ketoconazole
- SSRIs
- SNRIs
Contraindications
- Hypersensitivity to granisetron
- Children under 2 years
- Congenital long QT syndrome
Common side effects
- Headache
- Constipation
- Dizziness
- Somnolence
Counselling Points
- Administer prior to chemotherapy
- Monitor for signs of myocardial ischaemia
- Avoid in pregnancy and breastfeeding
Serious warnings
- May cause dysrhythmias
- Monitor for serotonin syndrome
- Risk of myocardial ischaemia
Important Disclaimer
The Granisetron 1 Mg/Ml (1 Ml) Fresenius, Granisetron 1 Mg/Ml (3 Ml) Fresenius 1 ml, 3 ml Concentrate for solution for injection/infusion. professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
